Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | PAM | P19021 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6599473 | 0.87 | TP53 (0.38) | ALDH1A1LMNA | |
| SCHEMBL3012608 | 0.78 | MAOB (0.49) | MAOBMAOAIDO1PAML3MBTL1 | |
| SCHEMBL1002069 | 0.78 | MAOB (0.49) | MAOBMAOAIDO1PAML3MBTL1 | |
| SCHEMBL3240426 | 0.76 | ALDH1A1 (0.39) | ALDH1A1CYP2A6MAOBMAOATSHR | |
| SCHEMBL8110092 | 0.75 | ALDH1A1 (0.42) | ALDH1A1CYP2A6MAOBMAOATSHR | |
| SCHEMBL6258270 | 0.75 | ALDH1A1 (0.42) | ALDH1A1CYP2A6MAOBMAOATSHR | |
| SCHEMBL16957356 | 0.74 | NFE2L2 (0.52) | NPC1RAB9A | |
| SCHEMBL16956466 | 0.74 | CHRM5 (0.47) | ALDH1A1MAOBGAA | |
| SCHEMBL1162641 | 0.73 | MAOA (0.36) | ALDH1A1CYP2A6MAOBMAOAL3MBTL1 | |
| Styrene SCHEMBL28107406 | 0.73 | ALDH1A1 (0.58) | ALDH1A1MAOBMAOATSHRIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023214119-A1 | AZETIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, PREPARATION METHODS AND THEIR USES IN THE TREATMENT OF CNS DISORDERS | EQUINORM LTD (FI) | 2023-11-09 | — | — | WO | claimed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | claimed |
| WO-2007130499-A2 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| EP-1594835-A4 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS INC (US) | 2007-05-02 | — | — | EP | claimed |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | HONG BORCHERNG | 2006-08-03 | — | — | US | claimed |
| EP-1594835-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | Auspex Pharmaceuticals, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| WO-2004064745-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| EP-0477646-B1 | Substituted 5-alkoxy-1,2,4-triazol-3-(thi)ones | BAYER AG (DE) | 1995-03-01 | — | — | EP | claimed |
| EP-0283876-B1 | Substituted triazolinones | BAYER AG (DE) | 1994-07-20 | — | — | EP | claimed |
| EP-0294666-B1 | Substituted triazolinones | BAYER AG (DE) | 1994-02-16 | — | — | EP | claimed |
| US-5276008-A | Herbicides and plant growth regulators | BAYER AKTIENGESELLSCHAFT (DE) | 1994-01-04 | — | — | US | claimed |
| EP-0332991-B1 | Substituted triazoles | BAYER AG (DE) | 1993-11-10 | — | — | EP | claimed |
| EP-0398096-B1 | SUBSTITUTED TRIAZOLONES | BAYER AG (DE) | 1993-10-13 | — | — | EP | claimed |
| EP-0412358-B1 | 3-AMINO-5-AMINOCARBONYL-1,2,4-TRIAZOLE DERIVATIVES | BAYER AG (DE) | 1993-09-29 | — | — | EP | claimed |
| EP-0415196-B1 | SUBSTITUTED 4,5-DIAMINO-1,2,4-TRIAZOL-3-(THI)ONES | BAYER AG (DE) | 1993-03-24 | — | — | EP | claimed |
| EP-0399285-B1 | PROCESS FOR THE PREPARATION OF 3-AMINO-5-AMINOCARBONYL-1,2,4-TRIAZOLE DERIVATIVES | BAYER AG (DE) | 1992-09-30 | — | — | EP | claimed |
| US-5082490-A | HERBICIDAL SUBSTITUTED 4,5-DIAMINO-1,2,4-TRIAZOL-3-(THI)ONES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-01-21 | — | — | US | claimed |
| US-5061311-A | SUBSTITUTED TRIAZOLINONE HERBICIDES AND PLANT GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1991-10-29 | — | — | US | claimed |
| EP-0298371-B1 | SUBSTITUTED TRIAZOLINONES | BAYER AG (DE) | 1991-10-02 | — | — | EP | claimed |
| US-5051517-A | Reacting a chloroformidine hydrochloride with an oxamohydrazide, forming bonds between carbon and nitrogen and cyclization | BAYER AKTIENGESELLSCHAFT (DE) | 1991-09-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ALDH1A1 1759/4885CYP2A6 2507/4885MAOB 3428/4885 |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | LSS, DHPS, CYP51A1 | ALDH1A1 1435/4885CYP2A6 51/4885MAOB 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.